The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings
暂无分享,去创建一个
S. Gove | C. Gilks | Marco Vitoria | S. Crowley | R. Ekpini | J. Perriens | Y. Souteyrand | D. Sutherland | M. Vitoria | T. Guerma | K. D. Cock | Teguest Guerma | Charles F Gilks | Siobhan Crowley | René Ekpini | Sandy Gove | Jos Perriens | Yves Souteyrand | Don Sutherland | Kevin De Cock
[1] R. Horton,et al. Public health in the new era: improving health through collective action , 2004, The Lancet.
[2] S. Swaminathan,et al. Increasing Nevirapine Dose Can Overcome Reduced Bioavailability Due to Rifampicin Coadministration , 2006, Journal of acquired immune deficiency syndromes.
[3] Anthony D Harries,et al. Supervision, monitoring and evaluation of nationwide scale-up of antiretroviral therapy in Malawi. , 2006, Bulletin of the World Health Organization.
[4] I. James,et al. Recovery of CD4+ T Cells in HIV Patients With a Stable Virologic Response to Antiretroviral Therapy Is Associated With Polymorphisms of Interleukin-6 and Central Major Histocompatibility Complex Genes , 2006, Journal of acquired immune deficiency syndromes.
[5] P. Kaleebu,et al. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa , 2006, AIDS.
[6] James Curran,et al. Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach , 2005 .
[7] I. Bates,et al. Evaluation of microscope condition in Malawi. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[8] Bg Gazzard and. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. , 2005, HIV medicine.
[9] Guilbert Jj. The World Health Report 2006: working together for health. , 2006 .
[10] C. Gilks,et al. National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines? , 2006, AIDS.
[11] C. Duncombe,et al. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children adolescents and adults. Recommendations for a public health approach. , 2006 .
[12] A. Huitema,et al. Indinavir/ritonavir‐based therapy in HIV‐1‐infected antiretroviral therapy‐naive patients: comparison of 800/100 mg and 400/100 mg twice daily , 2005, HIV medicine.
[13] J. Sterne,et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries , 2006, The Lancet.
[14] Christopher D Pilcher,et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. , 2004, The New England journal of medicine.
[15] N. Ford,et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment , 2006, The Lancet.
[16] J. Gallant,et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. , 2005, The Journal of infectious diseases.